Mr Mark Kotter MD MPhil PhD
Dr Kotter is an academic neurosurgeon at the University of Cambridge specialising in spinal surgery.
He graduated with distinction from the University of Graz, and obtained MPhil/PhD degrees studying neural regeneration at the University of Cambridge in the laboratory of Prof. Robin Franklin. He underwent neurosurgery training at the Medical University Vienna and the University of Cambridge and sub specialist training in complex spinal surgery with Prof. Michael Fehlings, University of Toronto.
His research focus is regenerative medicine and spinal cord injury. A particular interest is degenerative cervical myelopathy, the most common form of spinal cord dysfunction of adulthood. As the lead for academic spine, Dr Kotter is tasked with building a translational research program for spinal pathologies in Cambridge.
Supported by a Clinician Scientist Award from the National Institute for Health Research (NIHR) and in collaboration with www.myelopathy.org and MediciNova, his team translates findings made in his basic science lab into the first regenerative medicine trial for cervical myelopathy (RECEDE Myelopathy).
Dr Kotter leads a basic science research lab investigating mechanisms of regeneration of the Central Nervous System and cellular reprogramming.
Part 2 of the Cervical Myelopathy Documentary
| Clinical and Translational Research | Stem Cells and Cellular Reprogramming |
Publications
Research Impact
- Clinical research in Dr Kotter’s lab led to the foundation of www.myelopathy.org, the first charity dedicated to Degenerative Cervical Myelopathy.
- His basic science lab discovered that inhibition of phosphodiesterase 4 is able to promote remyelination; this forms the foundation for RECEDE Myelopathy, the first regenerative medicine trial for degenerative cervical myelopathy.
- Development of Opti-OX, a technology that enables efficient reprogramming of human stem cells, resulted in the foundation of
- www.bit.bio, a University of Cambridge Spin Out developing human cells for research, drug discovery, and cell therapy, and
- www.meatable.com, a Dutch company aiming to reduce our carbon footprint and increase animal welfare by providing cultured meat.
